British switch specialist Maxwellia has received an injection of funding via the the BioCity angel investment platform, which it says will be used to support prescription-to-OTC reclassifications in the area of women’s health and wellness.
Two of these switches were currently undergoing the approval process with the Medicines and Healthcare products Regulatory Agency (MHRA), BioCity revealed, moving Maxwellia – the “world’s first Rx-to-OTC switch incubator” –